Dharmesh Patel, MD
Cardiovascular Disease · Southaven, MSNPI 1689651036
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,171,629 of the $1,546,955 with a category attached, or 75.7%. 52 manufacturers reported payments, led by Johnson & Johnson at 30.5% of the total. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,272 payments — averaging $680.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$472K
- Amgen$331K
- Bayer$145K
- Novo Nordisk$108K
- Lilly USA, LLC$103K
- Esperion Therapeutics, Inc.$76K
- plus $312K from 46 others
Across 47 payments — averaging $8231.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$382K
- Amryt Pharma Holdings Ltd$4K
- Chiesi USA, Inc.$1K
What the payments were for
- Consulting fees$177,29011%
- Speaking & faculty fees$1,171,62976%
- Travel & lodging$152,20210%
- Food & beverage$45,5093%
- Education$2740%
- Entertainment$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$466,389
- Repatha$312,163
- JARDIANCE$168,463
- Kerendia$137,404
- Wegovy$74,829
- NEXLETOL$73,543
- NEXLIZET$73,068
- Vascepa$68,514
- FARXIGA$50,758
- ENTRESTO$26,282
- SYMPLICITY G3$24,574
- OLEZARSEN$9,689
- XIFAXAN$5,875
- LEQVIO$5,129
- LOKELMA$4,975
- Ozempic$4,650
- EVKEEZA$3,590
- COREVALVE EVOLUT R$1,540
- NOT Specifically Atributed$1,000
- TRYNGOLZA$550
How this compares
$1,546,955 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 1,243 | $1,157,578 |
| EntrestoSacubitril/Valsartan | 603 | $600,787 |
| JardianceEmpagliflozin | 524 | $528,896 |
| Repatha SureclickEvolocumab | 597 | $424,648 |
| EliquisApixaban | 326 | $305,134 |
| FarxigaDapagliflozin Propanediol | 253 | $246,608 |
| VascepaIcosapent Ethyl | 238 | $151,523 |
| OzempicSemaglutide | 89 | $86,978 |
| MultaqDronedarone Hcl | 54 | $60,744 |
| KerendiaFinerenone | 65 | $50,377 |
| NexlizetBempedoic Acid/Ezetimibe | 72 | $50,267 |
| Ezetimibe | 1,471 | $29,923 |
| MounjaroTirzepatide | 24 | $27,220 |
| BrilintaTicagrelor | 42 | $26,792 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 67 | $25,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $471,871 | $1,157,5781,243 claims |
| NovartisEntresto | $33,274 | $600,787603 claims |
| Boehringer IngelheimJardiance | $68,602 | $528,896524 claims |
| PfizerEliquis | $614 | $305,134326 claims |
| AstraZenecaFarxiga, Brilinta | $57,606 | $273,400295 claims |
| Novo NordiskOzempic, Wegovy | $108,335 | $102,632101 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $75,845 | $65,82896 claims |
| Sanofi-aventis U.S. LLCMultaq | $4,318 | $60,74454 claims |
| BayerKerendia | $145,389 | $50,37765 claims |
| Lilly USA, LLCMounjaro | $103,171 | $27,22024 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $1,338 | $25,42767 claims |
| MerckVerquvo | $4,338 | $16,12224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Southaven
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
- Matthew HannKeesler Afb$40K
- Tahsin QarqishJackson$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.